BridgeBio

BridgeBio is a biotechnology company that focuses on genetic disease therapies and develops those assets with the right approach in supporting R&D. BridgeBio creates a bridge from advancements in genetic science to patients with unmet needs via the entrepreneurial engine required to make life-changing medicines as rapidly as possible. BridgeBio's mission is to discover, create, test, and deliver transformative medicines to treat patients with genetic diseases.

Charles Homcy

Co-Founder

Thomas Trimarchi

President and COO

6 past transactions

Eidos Therapeutics

Acquisition in 2020
Eidos Therapeutics, Inc. is a clinical stage biopharmaceutical company based in San Francisco, California, that specializes in developing treatments for diseases related to transthyretin (TTR) amyloidosis. The company is advancing AG10, an orally administered small molecule currently in phase 3 clinical trials, which aims to stabilize tetrameric TTR and interrupt the molecular processes leading to amyloidosis. Founded in 2013, Eidos Therapeutics operates as a subsidiary of BridgeBio Pharma, which focuses on creating genetically targeted therapies designed to address the underlying causes of various diseases. Through its innovative approach, Eidos Therapeutics seeks to provide potentially disease-modifying therapies to meet the significant medical needs associated with TTR-related conditions.

Eidos Therapeutics

Series B in 2018
Eidos Therapeutics, Inc. is a clinical stage biopharmaceutical company based in San Francisco, California, that specializes in developing treatments for diseases related to transthyretin (TTR) amyloidosis. The company is advancing AG10, an orally administered small molecule currently in phase 3 clinical trials, which aims to stabilize tetrameric TTR and interrupt the molecular processes leading to amyloidosis. Founded in 2013, Eidos Therapeutics operates as a subsidiary of BridgeBio Pharma, which focuses on creating genetically targeted therapies designed to address the underlying causes of various diseases. Through its innovative approach, Eidos Therapeutics seeks to provide potentially disease-modifying therapies to meet the significant medical needs associated with TTR-related conditions.

QED Therapeutics

Venture Round in 2018
QED Therapeutics, a subsidiary of BridgeBio Pharma, is a biotechnology company focused on precision medicine for FGFR-driven disorders. Their lead candidate is infigratinib, a best-in-class FGFR kinase inhibitor that has shown meaningful clinical activity in chemotherapy-refractory cholangiocarcinoma with FGFR2 fusions. QED is also evaluating infigratinib in preclinical studies for the treatment of achondroplasia. They plan to develop infigratinib in additional FGFR-driven tumor types and rare disorders.

PellePharm

Series B in 2017
PellePharm, Inc. is a biopharmaceutical company based in Menlo Park, California, focused on researching and developing skin cancer therapeutics. The company is working on patidegib, a novel topical gel formulation that acts as a hedgehog pathway inhibitor, specifically designed to treat basal cell carcinomas (BCCs) and basal cell nevus syndrome, a rare genetic skin disease. By repurposing existing oral medications into a topical application, PellePharm aims to mitigate tumor burden and improve patient quality of life. The treatment seeks to reduce the need for invasive surgeries and the associated complications, such as scarring. Currently, patidegib is undergoing phase 2 clinical trials to assess its effectiveness in treating sporadic BCCs. Since its incorporation in 2012, PellePharm has remained dedicated to advancing innovative solutions in skin cancer care.

MyoKardia

Series B in 2015
MyoKardia, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing targeted therapies for rare cardiovascular diseases. Founded in 2012 and headquartered in Brisbane, California, the company primarily addresses heritable cardiomyopathies and genetically-driven heart failure caused by biomechanical defects in cardiac muscle contraction. Its lead product candidate, Mavacamten, is an orally administered allosteric modulator of cardiac myosin currently in Phase III trials for hypertrophic cardiomyopathy (HCM). Additionally, MyoKardia is developing Danicamtiv, an orally administered small molecule that has completed Phase I and IIa trials for dilated cardiomyopathy. The company also has several preclinical programs, including MYK-224 for HCM, ACT-1 for diastolic dysfunction, and LUS-1 for diastolic dysfunction. As of late 2020, MyoKardia operates as a subsidiary of Bristol-Myers Squibb Company.

MyoKardia

Venture Round in 2014
MyoKardia, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing targeted therapies for rare cardiovascular diseases. Founded in 2012 and headquartered in Brisbane, California, the company primarily addresses heritable cardiomyopathies and genetically-driven heart failure caused by biomechanical defects in cardiac muscle contraction. Its lead product candidate, Mavacamten, is an orally administered allosteric modulator of cardiac myosin currently in Phase III trials for hypertrophic cardiomyopathy (HCM). Additionally, MyoKardia is developing Danicamtiv, an orally administered small molecule that has completed Phase I and IIa trials for dilated cardiomyopathy. The company also has several preclinical programs, including MYK-224 for HCM, ACT-1 for diastolic dysfunction, and LUS-1 for diastolic dysfunction. As of late 2020, MyoKardia operates as a subsidiary of Bristol-Myers Squibb Company.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.